Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

First International Summit on Interventional Pharmacoeconomics

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Oct

Today In Oncology

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

The Molecular Watchman Why Measurable Residual Disease Testing Is Redefining Treatment and Surveillance in Colorectal and Bladder Cancers

Tile-Based Radiation Outperforms Postoperative Stereotactic Radiation Therapy in Resected Brain Metastases

Replacing Intensive Chemotherapy With Blinatumomab Improves Outcomes in High-Risk Pediatric Acute Lymphoblastic Leukemia

Pediatric and Adolescent Colorectal Carcinoma: A Retrospective Analysis

Autonomous AI Triaged Urgent Suspected Skin Cancer Referrals in Real-World Implementation Study